Dr Reddy’s Laboratories (UK) Limited v Boehringer Ingelheim International GMBH [2026] EWHC 2944 (Pat)

The Claimant, “DRL”, sought a declaration of invalidity in respect of the Defendant’s, “BI’s”, European Patent (UK) No. 1 730 131 B1 (“EP 131”), its associated SPC (the “SPC”), and European Patent (UK) No. 1 888 552 B1 (“EP 552“).  BI counterclaimed for infringement.

Each of EP 131, the SPC and EP 552 were asserted by BI to protect its commercial product empagliflozin, which is an anti-diabetic medication which improves glucose control in patients with type-2 diabetes through sodium-glucose-cotransporter-2 (“SGLT2”) inhibition.

DRL’s principal attack on both patents was lack of plausibility such that the claims are insufficient. DRL also contended that EP 552 lacks industrial application.

As to EP 131, BI argued that the patent’s cascade of preferences would lead the skilled team to understand that a group of 15 preferred compounds, including empagliflozin, had been made, tested and shown to possess SGLT activity. Meade LJ rejected that argument as impermissible “detective work”, holding that the patent did not disclose that any SGLT testing had been carried out. He also rejected BI’s alternative structural or “glucose” argument, noting that it lacked support from BI’s medicinal chemistry evidence and had not been properly put to DRL’s experts.

Meade LJ also made contingent findings in case the law on plausibility changes. In particular, he found that empagliflozin’s unusual tetrahydrofuran substituent, including its size, polarity and non-planar conformation, provided positive reasons to doubt that it would possess SGLT inhibitory activity.

Although EP 131 did not plausibly disclose SGLT inhibitory activity, Meade LJ held that EP 552 nevertheless made a plausible technical contribution and was industrially applicable. A stable crystalline form of empagliflozin would facilitate testing of whether the compound had SGLT activity and therefore provided a real, non-speculative utility.

Meade LJ ultimately held: i) EP 131 was invalid for obviousness and/or insufficiency arising from lack of plausibility; ii) the SPC is invalid as a result; and iii) EP 552 was valid while in force such that DRL’s proposed activities would have infringed it had they not been restrained by the interim injunction.

Mark Vanhegan KC, Adam Gamsa and Seaghan Davey acted for the DRL parties, instructed by Mishcon de Reya LLP.

[2026] EWHC 2944 (Pat)

Latest News

Quentin Schaefer joins 11 South Square

Chambers is delighted to announce Quentin Schaefer has accepted an offer of tenancy after a successful pupillage and will commence practice immediately....

Legal 500 Awards 2026

Jacqueline Reid wins Intellectual Property Junior of the Year at the Legal 500 Awards 2026.

Managing IP EMEA Awards 2026

Brian Nicholson KC wins Senior IP Barrister of the Year at the Managing IP EMEA Awards 2026.

Kathryn Pickard appointed King’s Counsel

Chambers is delighted to announce that Kathryn Pickard has been appointed King’s Counsel in the 2024 competition, announced on 24th January 2025.

Anna Edwards-Stuart appointed King’s Counsel

Chambers is delighted to announce that Anna Edwards-Stuart has been appointed King’s Counsel in the 2023 competition, announced on 19th January 2024.

Miruna Bercariu joins 11 South Square

Chambers is delighted to announce Miruna Bercariu has accepted an offer of tenancy after a successful pupillage and will commence practice immediately....

Chambers UK Bar Awards 2023

Chambers is thrilled to announce we have won all three of the awards we were nominated for at the Chambers UK Bar Awards 2023. 11 South Square, IT/IP Set of the Year Brian Nicholson KC, IT/IP Silk of the Year Ka...

Edward Cronan joins 11 South Square

We are pleased to announce the arrival of a new member of chambers, Edward Cronan. Edward first came on to our radar at 11 South Square when he was a solicitor, and we watched his move to the bar in 2018 with interest. S...

Bio-science Law Review – University Inventions: When is a student a consumer?

University Inventions: When is a student a consumer? Oxford University Innovation Limited v Oxford Nanoimaging Limited [2022] EWHC 3200 (Pat) This article provides a case comment on the Judgment of Daniel Alexander KC...

Michael Silverleaf called to the Irish Bar

Chambers is pleased to announce that Michael Silverleaf has been called to the Irish Bar and has appeared in that role as part of a team representing Bristol-Myers Squibb in the Irish High Court before Barrett J. The tri...